Study Summary
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T-cell products targeting CLL-1, CD33, CD38 and CD123 in patients with relapsed and refractory AML. The study also aims to learn more about the function of the universal CAR T cells and their persistency in AML patients.
Want to learn more about this trial?
Request More InfoInterventions
CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cellsBIOLOGICAL
Infusion of CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Shenzhen Geno-Immune Medical Institute | Shenzhen | Guangdong | China |